Subarachnoid hemorrhage medical therapy

Subarachnoid Hemorrhage Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Subarachnoid Hemorrhage from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2012) Risk Factors/Prevention Natural History/Outcome Clinical Manifestations/Diagnosis Medical Measures to Prevent Rebleeding Surgical and Endovascular Methods Hospital Characteristics/Systems of Care Anesthetic Management Cerebral Vasospasm and DCI Hydrocephalus Seizures Associated With aSAH Medical Complications
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Subarachnoid hemorrhage medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Subarachnoid hemorrhage medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Subarachnoid hemorrhage medical therapy
CDC on Subarachnoid hemorrhage medical therapy
Subarachnoid hemorrhage medical therapy in the news
Blogs on Subarachnoid hemorrhage medical therapy
Directions to Hospitals Treating Subarachnoid hemorrhage
Risk calculators and risk factors for Subarachnoid hemorrhage medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hasnain Ali Moryani, MBBS[2] Cafer Zorkun, M.D., Ph.D. [3] Sara Mehrsefat, M.D. [4]

Medical Therapy

The first priority in aneurysmal subarachnoid hemorrhage (aSAH) is the stabilization of the patient, prevention of rebleeding, and mitigation of delayed cerebral ischemia (DCI) and other systemic complications. All patients with confirmed aSAH should be admitted to a neurocritical care unit or high-acuity intensive care unit (ICU) for continuous hemodynamic and neurological monitoring.

Acute Management of Subarachnoid Hemorrhage

Medical Condition	Management
Initial Stabilization	Airway & Ventilation: Endotracheal intubation and mechanical ventilation for Glasgow Coma Scale (GCS) ≤8, elevated intracranial pressure (ICP), hemodynamic instability, or inability to protect the airway. Lung-protective ventilation strategies as part of bundled care are supported by observational data and recommended by the AHA/ASA 2023 guideline, though the only RCT in acute brain injury (PROLABI, 2024) did not confirm benefit and was stopped early. Monitoring: Continuous arterial blood pressure monitoring (arterial line), pulse oximetry, cardiac telemetry, and serial neurological exams. Nutrition & Mobilization: Early enteral nutrition (oral or nasogastric) is preferred over parenteral routes. Early mobilization should be integrated into bundled care. Analgesia: Acetaminophen is first-line. Pain control should utilize agents that minimize sedation to preserve the reliability of clinical exams.
Blood Pressure Control	Before aneurysm repair: Gradual reduction of blood pressure is reasonable for severe hypertension (SBP >180–200 mmHg). No specific target is validated; strict avoidance of hypotension (MAP <65 mmHg) is critical. Nimodipine may increase the blood pressure-lowering effect of concomitantly administered antihypertensives (e.g., diuretics, beta-blockers, ACE inhibitors). Preferred agents: Intravenous labetalol and nicardipine are preferred. Avoid nitroprusside and nitroglycerin due to the risk of ICP elevation. After aneurysm repair: Permissive hypertension is practiced. Antihypertensives should be avoided unless blood pressure is substantially elevated.
Elevated Intracranial Pressure (ICP) & Hydrocephalus	CSF Diversion: External ventricular drain (EVD) for symptomatic acute hydrocephalus (especially with depressed consciousness). Prophylactic lumbar drainage (e.g., 5 mL/hour, started within 72 hours) is supported by RCT evidence (EARLYDRAIN trial) and may be reasonable for patients without obstructive hydrocephalus to reduce secondary infarctions and improve 6-month outcomes. The role of lumbar drainage in aSAH is being actively investigated. ICP Control: Osmotic therapy (mannitol, hypertonic saline). Avoid hyperventilation as it may exacerbate vasospasm.
Delayed Cerebral Ischemia (DCI) Prevention	Nimodipine: 60 mg enterally every 4 hours for 21 days (improves functional outcomes). Hemodynamics: Maintain euvolemia at all times. Prophylactic hypervolemia and prophylactic induced hypertension ("triple-H" therapy) are not recommended due to increased medical complications.
Seizure Management	New-onset seizures: Treat with antiseizure medication (ASM) for 7 days in patients with aSAH who present with seizures to reduce delayed seizure or hemorrhage risk. Prophylaxis: Routine prophylaxis is not recommended. May be considered only in high-risk patients (e.g., ruptured MCA aneurysm, intraparenchymal hemorrhage). Preferred agents: Levetiracetam is commonly used. Avoid phenytoin (associated with worse cognitive and functional outcomes; may also reduce nimodipine efficacy via CYP3A4 induction). Monitoring: Continuous EEG is recommended for patients with depressed consciousness and may play a role in DCI surveillance.
Hyponatremia	Goal: Maintain euvolemia. Strictly avoid fluid restriction as it promotes hypovolemia and precipitates DCI. Treatment: Fludrocortisone (0.1–0.2 mg twice daily) or hypertonic saline (e.g., 2% NaCl infusion) can be used. High-dose hydrocortisone is not preferred due to complications.
Venous Thromboembolism (VTE)	Mechanical prophylaxis: Intermittent pneumatic compression devices should be applied to all patients from admission. Pharmacological prophylaxis: Unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) should be initiated after aneurysm securement. Retrospective data support early initiation (e.g., within 24 hours) without increased intracranial hemorrhagic complications.
Systemic Management	Glycemic Control: Conventional control (normoglycemia) is recommended. Avoid intensive control (target 80–120 mg/dL) due to cerebral hypoglycemia risks. Fever Control: Acetaminophen is first-line. Surface or endovascular cooling may be utilized, though neither has shown functional outcome benefit. Aggressively pursue infection workups. Anemia: Anemia is associated with poor outcomes. The optimal transfusion threshold remains uncertain. The SAHARA trial (English et al., NEJM 2025; n=725) found no significant difference in unfavorable neurological outcomes at 12 months between liberal (≤10 g/dL) and restrictive (≤8 g/dL) transfusion strategies. However, a meta-analysis of 3 RCTs (n=966) suggests a liberal strategy (9–10 g/dL threshold) probably reduces unfavorable neurological outcomes and cerebral ischemia compared with a restrictive approach (7–8 g/dL).

Nimodipine Therapy

Nimodipine remains the only pharmacological agent proven to improve functional outcomes after aSAH (Class I recommendation). It is thought to provide neuroprotective effects rather than directly reversing angiographic vasospasm.

• Dosing: 60 mg enterally (oral or via nasogastric tube) every 4 hours for 21 days. It should be initiated as early as possible.
• Management of Hypotension: Disruption of nimodipine is independently associated with a greater incidence of DCI. If nimodipine causes significant blood pressure variability or mild hypotension, it should not be stopped; instead, temporarily reduce the dose to 30 mg or support blood pressure with intravenous fluids and vasopressors.
• Route: Only enteral administration is recommended.
• Timing: Per the FDA label, nimodipine must be started within 96 hours of SAH onset and administered 1 hour before or 2 hours after meals.
• Hepatic impairment: In patients with cirrhosis, the dose must be reduced to 30 mg every 4 hours due to significantly increased plasma levels (Cmax approximately double that in normals). Blood pressure and pulse should be monitored closely.
• Drug interactions: Strong CYP3A4 inhibitors (e.g., clarithromycin, azole antifungals, HIV protease inhibitors, nefazodone) are contraindicated with the nimodipine capsule formulation and should generally be avoided with the oral solution formulations (Nymalize, generic solution) due to risk of significant hypotension. Strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort) should generally be avoided as they may significantly reduce nimodipine efficacy. Patients on moderate or weak CYP3A4 inducers (e.g., rifabutin, barbiturates, carbamazepine, oxcarbazepine, phenytoin) or inhibitors (e.g., diltiazem, erythromycin, fluconazole, cimetidine) should be closely monitored, and a nimodipine dose adjustment may be required. Grapefruit juice should be avoided during nimodipine therapy due to CYP3A4 inhibition.
• IV administration is contraindicated: Inadvertent intravenous administration of nimodipine has resulted in death, cardiac arrest, and cardiovascular collapse. Syringes used for enteral administration should be labeled "Not for IV Use."

Treatment of Established Delayed Cerebral Ischemia (DCI)

For patients who develop symptomatic DCI, hemodynamic augmentation is the primary medical treatment.

• Induced Hypertension: Elevating blood pressure with vasopressors is reasonable in symptomatic patients. The only RCT (HIMALAIA) was stopped early due to lack of effect on cerebral perfusion and slow recruitment (41 of planned 240 patients enrolled), but observational data indicate improvement in approximately 80% of symptomatic patients. A retrospective study found significantly more patients in the norepinephrine group exhibited neurological improvement compared with phenylephrine (94% vs. 71%; P=0.01) and were discharged to home or acute rehabilitation (94% vs. 73%; P=0.02).
• Volume Status: Maintenance of euvolemia remains critical during hemodynamic augmentation; hypervolemia should be strictly avoided.

Anticoagulation Reversal

For patients taking anticoagulants at the time of hemorrhage, immediate anticoagulation reversal is strongly recommended. All antithrombotic agents (vitamin K antagonists, direct oral anticoagulants, heparins, and antiplatelet agents) must be discontinued, and appropriate reversal protocols for life-threatening intracranial hemorrhage should be initiated.

Cardiac Complications

Cardiac dysfunction (biomarker elevation, ECG changes, wall-motion abnormalities) is common after aSAH and is associated with greater risk of DCI and poor outcomes. Stress cardiomyopathy (including Takotsubo pattern) may present with severely decreased left ventricular ejection fraction or regional wall-motion abnormalities. The clinical challenge is differentiating stress cardiomyopathy from acute coronary syndrome, as both may share troponin elevation, ECG changes, and chest pain. An admission ECG is recommended for all patients. Management is generally supportive, as most cardiac dysfunction is reversible. However, severe cardiac dysfunction may limit the ability to perform hemodynamic augmentation if DCI develops, and inotropic support may be required.

Therapies Not Recommended for Routine Use

Current guidelines strongly advise against several previously used therapies due to lack of efficacy or potential for harm:

• Antifibrinolytic Therapy: Routine use of tranexamic acid (TXA) is not recommended. The ULTRA trial (Post R et al., Lancet 2021) demonstrated no significant improvement in functional outcomes despite a trend toward reduced rebleeding. A post hoc analysis confirmed no benefit in the aneurysmal SAH subgroup.
• Statins: Routine statin therapy is not recommended. For patients already taking statins before aSAH, continuation may be reasonable based on observational data suggesting worse outcomes with statin discontinuation after hemorrhagic stroke, though prospective data are lacking.
• Magnesium Sulfate: Routine intravenous magnesium sulfate has shown no benefit in cerebral infarction rates or mortality and is not recommended.
• Prophylactic Hypervolemia: Associated with increased medical complications (e.g., congestive heart failure, pulmonary edema) without reducing DCI.
• Antiplatelet Therapy: There is insufficient evidence to recommend routine antiplatelet therapy for the prevention of DCI.

Contraindicated Medications

Subarachnoid hemorrhage is considered an absolute contraindication to the use of the following medications:

• Alteplase
  • Alteplase (tPA): Subarachnoid hemorrhage is an absolute contraindication to intravenous alteplase per stroke guidelines due to the catastrophic risk of bleeding from an unsecured ruptured aneurysm.
• Nitroprusside and Nitroglycerin: These agents should be avoided for blood pressure management due to the potential for elevating intracranial pressure.

2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage

Management of Cerebral Vasospasm and DCI After aSAH: Recommendations

Class I

"1. Oral nimodipine should be administered to all patients with aSAH† (Level of Evidence: A)"

"2. Maintenance of euvolemia and normal circulating blood volume is recommended to prevent DCI (Level of Evidence: B)"

"3. Induction of hypertension is recommended for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it (Level of Evidence: B)"

†It should be noted that this agent has been shown to improve neuroogical outcomes but not cerebral vasospasm. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain.

Class III (Harm)

"1. Prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended (Level of Evidence: B)"

Class IIa

"1. Transcranial Doppler is reasonable to monitor for the development of arterial vasospasm (Level of Evidence: B)"

"2. Perfusion imaging with CT or magnetic resonance can be useful to identify regions of potential brain ischemia (Level of Evidence: B)"

"3. Cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy (Level of Evidence: B)"

Management of Seizures Associated With aSAH: Recommendations

Class III (Harm)

"1. The routine long-term use of anticonvulsants is not recommended (Level of Evidence: B)"

Class IIb

"1. The use of prophylactic anticonvulsants may be considered in the immediate posthemorrhagic period (Level of Evidence: B)"

"2. The routine long-term use of anticonvulsants may be considered for patients with known risk factors for delayed seizure disorder, such as prior seizure, intracerebral hematoma, intractable hypertension, infarction, or aneurysm at the middle cerebral artery (Level of Evidence: B)"

Management of Hydrocephalus Associated With aSAH: Recommendations

Class I

"1. aSAH-associated acute symptomatic hydrocephalus should be managed by cerebrospinal fluid diversion (EVD or lumbar drainage, depending on the clinical scenario) (Level of Evidence: B)"

"2. aSAH-associated chronic symptomatic hydrocepha- lus should be treated with permanent cerebrospinal fluid diversion (Level of Evidence: C)"

Class III (Harm)

"1. Weaning EVD over >24 hours does not appear to be effective in reducing the need for ventricular shunting (Level of Evidence: B)"

"2. Routine fenestration of the lamina terminalis is not useful for reducing the rate of shunt-dependent hydrocephalus and therefore should not be routinely performed. (Level of Evidence: B)"

Management of Cerebral Vasospasm and DCI After aSAH: Recommendations

Class I

"1. Oral nimodipine should be administered to all patients with aSAH† (Level of Evidence: A)"

"2. Maintenance of euvolemia and normal circulating blood volume is recommended to prevent DCI (Level of Evidence: B)"

"3. Induction of hypertension is recommended for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it (Level of Evidence: B)"

†It should be noted that this agent has been shown to improve neuroogical outcomes but not cerebral vasospasm. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain.

Class III (Harm)

"1. Prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended (Level of Evidence: B)"

Class IIa

"1. Transcranial Doppler is reasonable to monitor for the development of arterial vasospasm (Level of Evidence: B)"

"2. Perfusion imaging with CT or magnetic resonance can be useful to identify regions of potential brain ischemia (Level of Evidence: B)"

"3. Cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy (Level of Evidence: B)"